Patents by Inventor Daniel Tusé

Daniel Tusé has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9585954
    Abstract: A method for eliciting an immune response by contacting a mucosal surface utilizing a composition including an antigen, a NOD agonist, and a mucoadhesive, wherein the NOD agonist is N-Acetyl-muramyl-L-Alanyl-D-Glutamin-n-butyl-ester (“Murabutide”).
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: March 7, 2017
    Assignee: ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Melissa Herbst-Kralovetz, Charles J. Arntzen, Daniel Tusé
  • Publication number: 20140065185
    Abstract: A method for eliciting an immune response by contacting a mucosal surface utilizing a composition including an antigen, a NOD agonist, and a mucoadhesive, wherein the NOD agonist is N-Acetyl-muramyl-L-Alanyl-D-Glutamin-n-butyl-ester (“Murabutide”).
    Type: Application
    Filed: October 31, 2013
    Publication date: March 6, 2014
    Applicant: ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Melissa Herbst-Kralovetz, Charles J. Arntzen, Daniel Tusé
  • Publication number: 20120121710
    Abstract: Methods and compositions for eliciting an immune response to an antigen are disclosed. In certain aspects, these methods concern eliciting an immune response in a subject by administering to the mucosa of the subject a composition comprising a virus-like particle (“VLP”) and Murabutide.
    Type: Application
    Filed: March 26, 2010
    Publication date: May 17, 2012
    Applicant: Arizona Board of Regents for and on behalf of Arizona State University
    Inventors: Melissa Herbst-Kralovetz, Charles J. Arntzen, Daniel Tusé
  • Patent number: 7084256
    Abstract: A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in correctly folded, preferably soluble form without a need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without a need for exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's (or B cell) lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma.
    Type: Grant
    Filed: February 8, 2002
    Date of Patent: August 1, 2006
    Assignee: Large Scale Biology Corporation
    Inventors: Alison A. McCormick, Daniel Tusé, Stephen J. Reinl, John A. Lindbo, Thomas H. Turpen
  • Patent number: 6482799
    Abstract: This invention provides a novel anti-microbial system suitable for formulation in a wide variety of ophthalmic solutions. In particular the composition comprises an antimicrobial peptide that is an indolicidin and a buffer compatible with application to a mammalian eye, wherein the buffer is a Good's buffer or the buffer has a halide ion concentration less than 0.85 wt %. The compositions are useful for storing, cleaning, or disinfecting a contact lens. In particular the compositions are self-preserving upon lengthy storage, effective in cleaning and sterilizing contact lenses upon exposure of the lens to the composition, do not require the need for physical or thermal treatment of the lens and enable the immediate application of the lens to the eye without the need for neutralization, deactivation or washing.
    Type: Grant
    Filed: May 25, 1999
    Date of Patent: November 19, 2002
    Assignee: The Regents of the University of California
    Inventors: Daniel Tusé, Kristien Mortelmans, Leslie A. Hokama, Michael E. Selsted, Larry L. Chapoy, Michael H. Quinn